Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases.

Bradley Alexander McGregorLi ZhangKathryn P GrayGrace ShawCarolyn EvanEdoardo FranciniChristopher Sweeney

Published in: Prostate cancer and prostatic diseases (2020)

Our hospital registry data indicate a potential benefit in terms of SRE prevention for early use of antiresorptive BTT in combination with life prolonging CRPC therapies for patients with CRPC and at least 4 BM.

Keyphrases

prostate cancer
electronic health record
bone mineral density
healthcare
big data
soft tissue
acute care
adverse drug
human health
emergency department
bone loss
machine learning
bone regeneration
postmenopausal women
artificial intelligence